
Keywords: BD; Bipolar disorder; CRP; C-reactive protein; HCs; Healthy controls; IFN; Interferon; IL; Interleukin; LPS; Lipopolysaccharide; PHA; Phytohemagglutinin; PRISMA-P; Preferred reporting items for systematic review and meta-analysis protocols; sIL-R; Soluble